AR112900A1 - Compuesto derivado de pirazol y uso de este - Google Patents

Compuesto derivado de pirazol y uso de este

Info

Publication number
AR112900A1
AR112900A1 ARP180102593A ARP180102593A AR112900A1 AR 112900 A1 AR112900 A1 AR 112900A1 AR P180102593 A ARP180102593 A AR P180102593A AR P180102593 A ARP180102593 A AR P180102593A AR 112900 A1 AR112900 A1 AR 112900A1
Authority
AR
Argentina
Prior art keywords
group
substituted
unsubstituted
linked
halogen
Prior art date
Application number
ARP180102593A
Other languages
English (en)
Inventor
Young Gil Ahn
Ji Young Song
Chang Hee Park
Won Jeoung Kim
Ji Sook Kim
In Hwan Bae
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of AR112900A1 publication Critical patent/AR112900A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporcionan compuestos que tienen una actividad inhibidora de la desmetilasa-1 específica de lisina (LSD1), un isómero óptico, un solvato, un tautómero o una sal farmacéuticamente aceptable de estos que es eficaz para prevenir o tratar una enfermedad provocada por la activación anómala de LSD1. Reivindicación 1: Un compuesto representado por la fórmula (1), un isómero óptico, un solvato o un tautómero o una sal farmacéuticamente aceptable de este, caracterizado porque, en la fórmula (1), el anillo B es un grupo carbocíclico C₃₋₃₀ o un grupo heterocíclico C₁₋₃₀; X es C(R⁵) o N; cada uno de R¹(s) a R⁵ es independientemente un radical monovalente seleccionado entre hidrógeno, halógeno, un grupo ciano, un grupo hidroxi, un grupo tiol, un grupo nitro, un grupo alquilo C₁₋₂₀ sustituido o no sustituido, un grupo alquenilo C₂₋₂₀ sustituido o no sustituido, un grupo alquinilo C₂₋₂₀ sustituido o no sustituido, un grupo carbocíclico C₃₋₂₀ sustituido o no sustituido, un grupo heterocíclico C₁₋₂₀ sustituido o no sustituido, un grupo alcoxi C₁₋₂₀ sustituido o no sustituido, un grupo cicloalcoxi C₃₋₂₀ sustituido o no sustituido, un grupo alquiltio C₁₋₂₀ sustituido o no sustituido, un grupo ariloxi C₆₋₂₀ sustituido o no sustituido, un grupo ariltio C₆₋₂₀ sustituido o no sustituido, un grupo heteroariloxi C₁₋₂₀ sustituido o no sustituido, un grupo heteroariltio C₁₋₂₀ sustituido o no sustituido, un grupo alquilamino C₁₋₂₀ sustituido o no sustituido, un grupo arilo C₆₋₂₀ sustituido o no sustituido, un grupo heteroarilo C₁₋₂₀ sustituido o no sustituido, -N(Q¹)(Q²), -C(=O)(Q¹), -N-C(=O)(Q¹), -N-C(=O)-N(Q¹)(Q²), -O-C(=O)(Q¹), -S(=O)(Q¹), -S(=O)₂(Q¹), -P(=O)(Q¹)(Q²) y -N-C(=NH)-N(Q¹)(Q²), cuando R¹(s) o R²(s) es(son) opcionalmente dos o más, dos de R¹(s) o R²(s) son sustituyentes en dos átomos adyacentes del anillo que están conectados de manera consecutiva a un anillo correspondiente, dos sustituyentes adyacentes R¹(s) o R²(s) están conectados entre sí para formar un grupo carbocíclico C₃₋₃₀ sustituido o no sustituido o un grupo heterocíclico C₁₋₃₀ sustituido o no sustituido, para formar de esta manera un anillo condensado con el anillo correspondiente; R³ y R⁴ opcionalmente están unidos para formar un grupo heterocíclico C₁₋₃₀ sustituido o no sustituido con un nitrógeno de la amida de la fórmula 1; k es un número entero de 0 a 4; cuando k es 2 o más, al menos dos R¹(s) son idénticos o diferentes entre sí, y m es un número entero de 0 a 7; cuando m es 2 o más, al menos dos R²(s) son idénticos o diferentes entre sí; donde cada uno de Q¹ y Q² se selecciona independientemente entre hidrógeno, halógeno, un grupo hidroxi, un grupo alquilo C₁₋₁₀ sustituido o no sustituido, un grupo alquenilo C₂₋₁₀ sustituido o no sustituido, un grupo alquinilo C₂₋₁₀ sustituido o no sustituido, un grupo cicloalquilo C₃₋₁₀ sustituido o no sustituido, un grupo heterocicloalquilo C₁₋₁₀ sustituido o no sustituido, un grupo alcoxi C₁₋₁₀ sustituido o no sustituido, un grupo cicloalcoxi C₃₋₁₀ sustituido o no sustituido, un grupo alquiltio C₁₋₁₀ sustituido o no sustituido, un grupo ariloxi C₆₋₁₀ sustituido o no sustituido, un grupo ariltio C₆₋₁₀ sustituido o no sustituido, un grupo heteroariloxi C₁₋₁₀ sustituido o no sustituido, un grupo heteroariltio C₁₋₁₀ sustituido o no sustituido, un grupo alquilamino C₁₋₁₀ sustituido o no sustituido, un grupo arilo C₆₋₁₀ sustituido o no sustituido y un grupo heteroarilo C₁₋₁₀ sustituido o no sustituido. Reivindicación 11: Un compuesto representado por la fórmula (2), un isómero óptico, un solvato o un tautómero o una sal farmacéuticamente aceptable de este, caracterizado porque, en la fórmula (2), A es hidrógeno o un grupo alquilo C₁₋₄; cada uno del o los W(s) es independientemente halógeno; n es un número natural entre 1 y 4; Y es un grupo cicloalquilo C₃₋₆ sustituido o no sustituido, un grupo pirrolidinilo sustituido o no sustituido unido a través de N, o un grupo piperidinilo sustituido o no sustituido unido a través de N, donde el grupo cicloalquilo C₃₋₆ sustituido es un grupo cicloalquilo C₃₋₆ en el cual al menos un hidrógeno está sustituido con un grupo funcional, cada uno de los cuales se selecciona independientemente entre halógeno y un grupo hidroxi, y cada uno del grupo pirrolidinilo sustituido unido a través de N y el grupo piperidinilo sustituido unido a través de N es un grupo pirrolidinilo unido a través de N y un grupo piperidinilo unido a través de N, respectivamente, en los cuales al menos un átomo de hidrógeno del anillo ha sido sustituido por un grupo funcional, cada uno de los cuales se selecciona independientemente entre un grupo alquilo C₁₋₄, halógeno, un grupo alcoxi C₁₋₄, un grupo hidroxi y un grupo heterocíclico C₁₋₁₀; y Z es un grupo pirrolidinilo sustituido o no sustituido unido a través de N, un grupo piperidinilo sustituido o no sustituido unido a través de N o un grupo azepanilo sustituido o no sustituido unido a través de N, donde al menos un sustituyente del grupo pirrolidinilo sustituido unido a través de N, el grupo piperidinilo sustituido unido a través de N o el grupo azepanilo sustituido unido a través de N se selecciona entre un grupo amino, un grupo alquilamino C₁₋₄, un grupo alquilo C₁₋₄, halógeno, un grupo alcoxi C₁₋₄ y un grupo heterocíclico C₁₋₁₀.
ARP180102593A 2017-09-13 2018-09-12 Compuesto derivado de pirazol y uso de este AR112900A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20170117226 2017-09-13

Publications (1)

Publication Number Publication Date
AR112900A1 true AR112900A1 (es) 2019-12-26

Family

ID=65723753

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180102593A AR112900A1 (es) 2017-09-13 2018-09-12 Compuesto derivado de pirazol y uso de este

Country Status (8)

Country Link
US (1) US11254676B2 (es)
EP (1) EP3681877B1 (es)
JP (1) JP7181287B2 (es)
KR (1) KR102284205B1 (es)
CN (1) CN111094265B (es)
AR (1) AR112900A1 (es)
TW (1) TWI794294B (es)
WO (1) WO2019054766A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114105950B (zh) * 2020-08-31 2022-09-06 南京明德新药研发有限公司 吡唑类化合物及其应用
CA3231846A1 (en) 2021-04-08 2022-10-13 Tamara Maes Combinations of lsd1 inhibitors for treating myeloid cancers
WO2023217758A1 (en) 2022-05-09 2023-11-16 Oryzon Genomics, S.A. Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors
WO2023217784A1 (en) 2022-05-09 2023-11-16 Oryzon Genomics, S.A. Methods of treating nf1-mutant tumors using lsd1 inhibitors
WO2024110649A1 (en) 2022-11-24 2024-05-30 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors and menin inhibitors for treating cancer
WO2024137358A1 (en) * 2022-12-23 2024-06-27 Imago Biosciences, Inc. Kdm1a inhibitors for the treatment of disease

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH27357A (en) * 1989-09-22 1993-06-21 Fujisawa Pharmaceutical Co Pyrazole derivatives and pharmaceutical compositions comprising the same
US8084467B2 (en) * 1999-10-18 2011-12-27 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
US7393842B2 (en) * 2001-08-31 2008-07-01 University Of Connecticut Pyrazole analogs acting on cannabinoid receptors
AU2004200420A1 (en) * 2003-03-11 2004-09-30 Astellas Pharma Inc. Inhibitor of cyclooxygenase
TW200526641A (en) * 2003-12-26 2005-08-16 Daiichi Seiyaku Co Amidopyrazole derivatives
EP1928859A1 (en) * 2005-06-17 2008-06-11 Carex SA Pyrazole derivates as cannabinoid receptor modulators
EP1951678A1 (en) * 2005-10-21 2008-08-06 Mitsubishi Tanabe Pharma Corporation Pyrazole compounds having cannabinoid receptor (cb1) antagonizing activity
WO2012135113A2 (en) 2011-03-25 2012-10-04 Glaxosmithkline Llc Cyclopropylamines as lsd1 inhibitors
WO2012174362A1 (en) * 2011-06-17 2012-12-20 Research Triangle Institute Pyrazole derivatives as cannabinoid receptor 1 antagonists
EP3080100B1 (en) 2013-12-11 2022-11-30 Celgene Quanticel Research, Inc. Inhibitors of lysine specific demethylase-1
SG11201700007YA (en) 2014-07-03 2017-01-27 Celgene Quanticel Res Inc Inhibitors of lysine specific demethylase-1
US9695167B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors
TW201613925A (en) 2014-07-10 2016-04-16 Incyte Corp Imidazopyrazines as LSD1 inhibitors
DK3381896T3 (da) 2015-11-27 2023-03-27 Taiho Pharmaceutical Co Ltd Biphenylforbindelse eller salt deraf

Also Published As

Publication number Publication date
CN111094265B (zh) 2023-07-25
KR20190030192A (ko) 2019-03-21
EP3681877B1 (en) 2024-10-16
EP3681877A1 (en) 2020-07-22
JP2020533372A (ja) 2020-11-19
US20210009591A1 (en) 2021-01-14
JP7181287B2 (ja) 2022-11-30
TW201920135A (zh) 2019-06-01
TWI794294B (zh) 2023-03-01
CN111094265A (zh) 2020-05-01
KR102284205B1 (ko) 2021-08-02
US11254676B2 (en) 2022-02-22
WO2019054766A1 (en) 2019-03-21
EP3681877A4 (en) 2021-02-24

Similar Documents

Publication Publication Date Title
AR112900A1 (es) Compuesto derivado de pirazol y uso de este
PE20231935A1 (es) Moduladores de la via de estres integrada
AR108812A1 (es) Proceso para preparar un derivado de piridona policíclica sustituida y cristal del mismo
AR112689A1 (es) Agonistas del receptor tipo toll 7 (tlr7) que tienen porciones aromáticas ligadas al heteroátomo, conjugados de estos y métodos y usos de estos
AR091976A1 (es) Inhibidores de proteasa ns3 de vhc
AR114236A1 (es) Inhibidores de la gcn2 y usos de los mismos
AR089774A1 (es) Derivados de indolizina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
AR117617A1 (es) Compuestos de sulfonilurea como inhibidores de la actividad de interleuquina 1
AR077695A1 (es) Derivados de pirimidina como inhibidores del factor ixa
AR110405A1 (es) Compuestos
AR100809A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR100808A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
EA201690019A1 (ru) Производное аминотриазина и содержащая его фармацевтическая композиция
AR119010A1 (es) Compuestos, composiciones y métodos de uso
AR125425A1 (es) Inhibidores de proteina tirosina fosfatasa y sus metodos de uso
AR091498A1 (es) DERIVADOS DE 2,3-DIHIDRO-1H-IMIDAZO{1,2-a}PIRIMIDIN-5-ONA Y 1,2,3,4-TETRAHIDRO-PIRIMIDO{1,2-a}PIRIMIDIN-6-ONA QUE CONTIENEN UNA MORFOLINA SUSTITUIDA, SU PREPARACION Y SU UTILIZACION FARMACEUTICA
DOP2010000272A (es) Nuevos derivados de carbazol inhibidores de hsp90, composiciones que los contienen y utilizacion
AR107170A1 (es) Compuestos heterocíclicos tricíclicos condesados como inhibidores de integrasa del vih
AR103742A1 (es) Derivados de trifluorometilpropanamida
AR104555A1 (es) SULFONAS TRICÍCLICAS COMO MODULARES DE RORg
AR107042A1 (es) Inhibidores de la tirosina quinasa de bruton y métodos de su uso
AR085088A1 (es) Inhibidores de histona desacetilasa y composiciones farmaceuticas que los contienen
AR115007A1 (es) Derivados de triazolona o sales de los mismos y composiciones farmacéuticas que comprenden los mismos
AR099914A1 (es) Derivados de indol y de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
AR096709A1 (es) Ligandos sigma para la prevención y el tratamiento de dolor asociado a cistitis intersticial / síndrome de dolor vesical (ci / sdv)